OncoResponse has filed a notice of an exempt offering of securities to raise $40,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, OncoResponse is raising $40,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Clifford Stocks played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About OncoResponse
OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The companys lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics. OncoResponse is based in Seattle, Washington.
To learn more about OncoResponse, visit http://www.oncoresponseinc.com/
Contact:
Clifford Stocks, Chief Executive Officer
206-805-1600
https://www.linkedin.com/in/cliffordstocks/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.